Global oligonucleotide synthesis industry special project research and operation prospect analysis report
According to Bezos Consulting's research data, the global oligonucleotide synthesis market size will be $10.505 billion in 2024, and it is expected to increase to $22.783 billion by 2029.
Therapeutic oligonucleotides can be used to treat viral infections, respiratory diseases, cancer, and rare diseases such as Duchenne muscular dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura. In the past decade, the importance of synthetic oligonucleotides as therapeutic agents to treat diseases has increased significantly.
Market Drivers Analysis
The major factor driving the growth of the global oligonucleotide synthesis market is the growing focus on personalized genome sequencing, which helps determine the best approach for patient care, whether it is prevention, diagnosis, or treatment.
The increase in government-funded projects is also expected to have a positive impact on the overall growth of the oligonucleotide synthesis market.
In addition, countries such as China, India, and Singapore, as well as emerging economies such as Brazil, provide significant growth opportunities for the oligonucleotide synthesis market, mainly due to increasing R & D investments by companies in emerging economies in Asia Pacific and Latin America.
In 2024, oligonucleotide drugs will account for a large share, as oligonucleotide drugs, particularly antisense oligonucleotides and interfering RNAs, have become part of an increasing number of pharmaceutical and biotechnology programs for the treatment of multiple indications, including cancer, cardiovascular disease, neurodegenerative diseases, neuromuscular diseases, and respiratory diseases.
